Enrofloxacin: Bayer Sues Norbrook Over Bid to launch generic version

Bayer Healthcare has filed a lawsuit in District Court of Kansas against Norbrook Laboratories Ltd., accusing the veterinary pharmaceutical company of infringing Bayer’s patent for Enrofloxacin as it tries to bring a generic version of the antibacterial drug to market. Innovator in its complaint alleged Infringement of US5756506 (which covers a process for treating a bacterial infection in an animal in need thereof comprising administering to said animal a pharmaceutically effective composition comprising a fluoroquinolone, an ester, or a salt thereof in one high dose, single treatment), following the equivalent of a Paragraph IV certification as part of Norbrook's filing of its ANADA (Abbreviated New Animal Drug Application) to manufacture a generic version of Bayer's BAYTRIL® 100 (Enrofloxacin injection, used for the treatment of bovine respiratory disease in beef and non-lactating dairy cattle).